Regulatory perspectives and research activities at the FDA on the use of phantoms with in vivo diagnostic devices

Anant Agrawal; Marios A. Gavrielides; Sandy Weininger; Kish Chakrabarti; Joshua Pfefer

doi:10.1117/12.768537

21 February 2008 Regulatory perspectives and research activities at the FDA on the use of phantoms with in vivo diagnostic devices

Anant Agrawal, Marios A. Gavrielides, Sandy Weininger, Kish Chakrabarti, Joshua Pfefer

Author Affiliations +

Proceedings Volume 6870, Design and Performance Validation of Phantoms Used in Conjunction with Optical Measurements of Tissue; 687005 (2008) https://doi.org/10.1117/12.768537
Event: SPIE BiOS, 2008, San Jose, California, United States

Abstract

For a number of years, phantoms have been used to optimize device parameters and validate performance in the primary medical imaging modalities (CT, MRI, PET/SPECT, ultrasound). Furthermore, the FDA under the Mammography Quality Standards Act (MQSA) requires image quality evaluation of mammography systems using FDA-approved phantoms. The oldest quantitative optical diagnostic technology, pulse oximetry, also benefits from the use of active phantoms known as patient simulators to validate certain performance characteristics under different clinically-relevant conditions. As such, guidance provided by the FDA to its staff and to industry on the contents of pre-market notification and approval submissions includes suggestions on how to incorporate the appropriate phantoms in establishing device effectiveness. Research at the FDA supports regulatory statements on the use of phantoms by investigating how phantoms can be designed, characterized, and utilized to determine critical device performance characteristics. These examples provide a model for how novel techniques in the rapidly growing field of optical diagnostics can use phantoms during pre- and post-market regulatory testing.

Citation Download Citation

Anant Agrawal, Marios A. Gavrielides, Sandy Weininger, Kish Chakrabarti, and Joshua Pfefer "Regulatory perspectives and research activities at the FDA on the use of phantoms with in vivo diagnostic devices", Proc. SPIE 6870, Design and Performance Validation of Phantoms Used in Conjunction with Optical Measurements of Tissue, 687005 (21 February 2008); https://doi.org/10.1117/12.768537

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available